New eye injection tested for common causes of vision loss
Disease control
Completed
This early-stage study tested a new eye injection called EYE103. It aimed to check its safety and find the best dose for people with vision loss from diabetic macular edema (DME) or 'wet' age-related macular degeneration (NVAMD). For DME, it was tested alone; for NVAMD, it was te…
Phase: PHASE1, PHASE2 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC